Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Table 1 Changes in BCVA, visual field MD and ORT values after WJ-MSC applications in 34 eyes (32 patients)

No	Eye	BCVA		Visual field MD		Outer Retinal Thickness
No	Eye	Before	After	Before	After	Before	After
1	Rⁱ	100	110	28,3	27,7	85.0	152.2
2	Lⁱ	80	87	28,0	26,6	93.4	120.4
3	R^c	80	88	28,3	27,3	117.4	117.8
4	L^c	84	88	28,2	26,7	118.2	145.4
5	L^c	50	74	29,2	26,1	103.0	105.7
6	L^c	80	85	28,9	25,8	129.0	131.9
7	R^c	50	56	19.4	9,4	116.0	126.3
8	L^c	80	87	27,6	26,4	101.4	102.2
9	Lⁱ	72	79	25,3	19,2	79.2	135.6
10	Lⁱ	50	55	18,7	14,4	105.0	111.8
11	R^c	65	77	29,2	28,1	92.2	128.7
12	Rⁱ	65	74	29,6	28,8	128.2	145.6
13	Lⁱ	65	87	28,0	25,7	101.0	104.8
14	R^c	50	69	19,5	5,7	100.4	110.0
15	Lⁱ	89	110	28,4	16,4	84.8	120.0
16	Rⁱ	80	83	28,9	28,2	128.6	98.4
17	L^c	50	59	29,1	29,0	105.6	122.8
18	L^c	80	85	28,6	27,3	89.0	94.8
19	Rⁱ	50	65	26,1	23,9	82.6	109.0
20	R^c	60	77	13,9	13,3	84.2	86.8
21	R^c	50	59	29,9	29,4	85.2	97.0
22	Lⁱ	77	87	28,6	27,5	86.0	116.0
23	Rⁱ	70	70	25,5	25,6	91.0	91.6
24	Lⁱ	98	110	26,1	25,9	118.2	152.4
25	L^c	85	91	29,1	28,9	106.0	132.8
26	L^c	89	110	25,9	23,2	109.3	122.0
27	Rⁱ	85	94	28,8	28,7	120.2	135.8
28	Rⁱ	50	55	28,5	27,9	116.0	122.8
29	R^c	50	50	29,4	29,4	117.0	117.0
30	Lⁱ	89	94	27,4	25,2	110.0	140.4
31	R^c	74	85	28,9	27,6	101.0	106.0
	Lⁱ	80	87	28,6	28,1	96.9	101.3
32	R^c	60	77	29,4	29,4	70.4	111.8
	Lⁱ	60	77	28,1	27,7	72.6	112.4

BCVA best-corrected visual acuity, ETDRS early treatment of diabetic retinopathy study charts (letters point);
MD mean deviation (dB)
Outer retinal thickness (μm)
i: injection by 25 G sharp-tip needle
c: application by subtenon curved canulla with preplaced suture

ISSN: 1757-6512